ChromaDex Past Earnings Performance
Past criteria checks 0/6
ChromaDex hat die Erträge mit einer durchschnittlichen jährlichen Rate von 18.9% gesteigert, während die Branche Life Sciences die Erträge growing mit 20.7% jährlich steigerte. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 17.5% pro Jahr gestiegen.
Key information
22.1%
Earnings growth rate
27.4%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 16.3% |
| Return on equity | -17.4% |
| Net Margin | -5.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet
Feb 28
ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price
Jan 29Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues
Jun 08We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely
Mar 31ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé
Oct 11ChromaDex forms JV in Asia for Tru Niagen; plans to raise $3.1M via stock sale
Oct 03ChromaDex in pact to introduce anti-aging compound in Brazil
Sep 01Ayana Bio appoints Frank Jaksch as CEO
Aug 24ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent
Aug 15Some ChromaDex Corporation (NASDAQ:CDXC) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 15We're Not Very Worried About ChromaDex's (NASDAQ:CDXC) Cash Burn Rate
Mar 03Companies Like ChromaDex (NASDAQ:CDXC) Can Afford To Invest In Growth
Nov 19When Should You Buy ChromaDex Corporation (NASDAQ:CDXC)?
Sep 14We Discuss Whether ChromaDex Corporation's (NASDAQ:CDXC) CEO Is Due For A Pay Rise
Jun 11ChromaDex to sell Tru Niagen in 3,800 Walmart stores in the U.S.
Jun 07Is There Now An Opportunity In ChromaDex Corporation (NASDAQ:CDXC)?
Jun 02We Think ChromaDex (NASDAQ:CDXC) Can Easily Afford To Drive Business Growth
May 14Revenue & Expenses BreakdownBeta
How ChromaDex makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 84 | -5 | 51 | 5 |
| 30 Sep 23 | 83 | -6 | 52 | 5 |
| 30 Jun 23 | 81 | -6 | 52 | 5 |
| 31 Mar 23 | 77 | -11 | 54 | 5 |
| 31 Dec 22 | 72 | -17 | 57 | 5 |
| 30 Sep 22 | 69 | -20 | 60 | 5 |
| 30 Jun 22 | 69 | -28 | 66 | 4 |
| 31 Mar 22 | 70 | -27 | 66 | 4 |
| 31 Dec 21 | 67 | -27 | 65 | 4 |
| 30 Sep 21 | 65 | -28 | 65 | 4 |
| 30 Jun 21 | 62 | -23 | 59 | 4 |
| 31 Mar 21 | 60 | -21 | 55 | 3 |
| 31 Dec 20 | 59 | -20 | 52 | 3 |
| 30 Sep 20 | 57 | -23 | 51 | 4 |
| 30 Jun 20 | 55 | -26 | 52 | 4 |
| 31 Mar 20 | 51 | -30 | 52 | 4 |
| 31 Dec 19 | 46 | -32 | 53 | 4 |
| 30 Sep 19 | 42 | -32 | 49 | 5 |
| 30 Jun 19 | 38 | -33 | 48 | 5 |
| 31 Mar 19 | 35 | -33 | 46 | 5 |
| 31 Dec 18 | 32 | -33 | 44 | 5 |
| 30 Sep 18 | 30 | -34 | 43 | 6 |
| 30 Jun 18 | 28 | -29 | 37 | 5 |
| 31 Mar 18 | 24 | -23 | 29 | 5 |
| 30 Dec 17 | 21 | -17 | 22 | 4 |
| 30 Sep 17 | 18 | -10 | 14 | 3 |
| 01 Jul 17 | 16 | -8 | 11 | 3 |
| 01 Apr 17 | 18 | -6 | 11 | 3 |
| 31 Dec 16 | 22 | -4 | 11 | 3 |
| 01 Oct 16 | 22 | -3 | 10 | 2 |
| 02 Jul 16 | 24 | -2 | 10 | 2 |
| 02 Apr 16 | 24 | -1 | 10 | 1 |
| 02 Jan 16 | 18 | -3 | 9 | 1 |
| 03 Oct 15 | 22 | -3 | 9 | 1 |
| 04 Jul 15 | 20 | -3 | 9 | 1 |
| 04 Apr 15 | 18 | -5 | 10 | 1 |
| 03 Jan 15 | 15 | -5 | 10 | 1 |
| 27 Sep 14 | 13 | -5 | 10 | 0 |
| 28 Jun 14 | 12 | -5 | 9 | 0 |
| 29 Mar 14 | 11 | -5 | 8 | 0 |
| 28 Dec 13 | 10 | -4 | 7 | 0 |
| 28 Sep 13 | 11 | -5 | 9 | 0 |
| 29 Jun 13 | 12 | -6 | 9 | 0 |
Qualität der Erträge: CDXC ist derzeit unrentabel.
Wachsende Gewinnspanne: CDXC ist derzeit unrentabel.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Ergebnisentwicklung: CDXC ist unrentabel, hat aber in den letzten 5 Jahren die Verluste mit einer Rate von 18.9% pro Jahr reduziert.
Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von CDXC verglichen werden, da das Unternehmen derzeit nicht profitabel ist.
Erträge im Vergleich zur Industrie: CDXC ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Life Sciences (-11.4%) erschwert.
Return on Equity
Hohe Eigenkapitalrendite: CDXC hat eine negative Eigenkapitalrendite (-23.69%), da es derzeit unrentabel ist.